Takeda Reports FY2024 Revenue of $30.6 Billion with 14.7% Growth in Product Sales

On May 8, Takeda announced the fiscal year 2024(As of March 31, 2025)The earnings report. The report shows that Takeda successfully achieved growth in revenue and core operating profit in the fiscal year 2024:

• Total Revenue: 4,579.8 Billion Yen (30.6 Billion USD), Year-over-Year Growth of +2%(Calculated by CER, the same below)；

• Core operating profit 1,162.6 billion yen (7.8 billion USD), up 4.9% year-on-year，Core operating profit margin reaches 25.4%。

Takeda focuses on the research and development in four major therapeutic areas: oncology, gastroenterology, neuroscience, and rare diseases, with targeted R&D investments in blood products and vaccines. In the fiscal year 2024, TakedaProduct revenue reached 2,201.9 billion yen ($14.7 billion), representing a year-on-year increase of 14.7% and contributing to 48% of the company's total revenue.。

Regarding the impact of tariffs on the company's revenue, Takeda believes that its potential risk from U.S. and Chinese tariffs is limited:

• Approximately 50% of Takeda's total revenue comes from the United States, with imports amounting to(Mainly from Europe/Japan/Singapore)Accounting for approximately 8% to 10% of total revenue in the United States.

• Approximately 4% of Takeda's total revenue comes from China, with imports amounting to(From the United States)Accounting for approximately 12% to 15% of China's total revenue.

• For imported products that may be affected by potential tariffs, Takeda is taking mitigation measures.(For example, inventory and supply chain management)。

In the fiscal year 2025, Takeda will have up to six new molecular entities in Phase III development, with data from three Phase III clinical trials recently completed or expected to be completed.Takeda Projects Flat Revenue, Profit For Fiscal 2025。

Scan the WeChat QR code, add the editor of Antibody Circle, and those who meet the requirements can join the Antibody Circle WeChat group!

Please indicate: Name + Research Direction!

All reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted can contact us (cbplib@163.com), and we will delete the content immediately. All articles represent the views of the author and do not represent the position of this website.